In Vitro ELISA Test to Evaluate Rabies Vaccine Potency

Overview

This article describes an indirect ELISA sandwich immunocapture method for determining the immunogenic glycoprotein contents in rabies vaccines. The test utilizes a neutralizing Monoclonal Antibody (mAb-D1) that recognizes glycoprotein trimers, providing an alternative to the in vivo NIH test for assessing vaccine potency.

Key Study Components

Area of Science

• Immunology
• Vaccinology
• In vitro testing methods

Background

• The WHO encourages the development of in vitro approaches to reduce animal testing.
• Variability in the NIH test has prompted the search for more consistent alternatives.
• This ELISA test demonstrates good concordance with classical NH tests.
• High sensitivity and rapid execution within one day are key advantages of this method.

Purpose of Study

• To evaluate rabies vaccine potency using an in vitro ELISA method.
• To provide a reliable alternative to the in vivo NIH test.
• To promote the use of this method among manufacturers and national control laboratories.

Methods Used

• Indirect ELISA sandwich immunocapture technique.
• Use of neutralizing Monoclonal Antibody (mAb-D1).
• Preparation of pre-sized volumes in duplicate for each dilution.
• Decontamination procedures for handling contaminated materials.

Main Results

• The ELISA test shows high sensitivity in recognizing the immunogenic form of the glycoprotein.
• Results are consistent with those obtained from classical NH tests.
• The method can be completed in a single day, enhancing efficiency.
• Promoted as a viable alternative by manufacturers and control laboratories.

Conclusions

• The ELISA method is a promising alternative for evaluating rabies vaccine potency.
• It aligns with WHO recommendations to reduce animal testing.
• Further adoption could standardize vaccine potency assessments.

Frequently Asked Questions